You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 41 No. 8, August 1984 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Interdosage Fluctuations in Plasma Carbamazepine Concentration Determine Intermittent Side Effects

Torbjörn Tomson, MD

Arch Neurol. 1984;41(8):830-834.


Abstract

• Fluctuations in plasma carbamazepine concentrations were related to side effects in five epileptics. One patient was receiving only carbamazepine; four were receiving carbamazepine plus phenobarbital sodium or phenytoin sodium. The patients were studied during two 12-hour periods: carbamazepine given (1) twice daily or (2) four times daily. Concomitant medication regimens were kept constant; administration was single-blind. Plasma concentrations of carbamazepine, carbamazepine's epoxide metabolite, phenobarbital, and phenytoin were determined hourly; side effects were assessed simultaneously. Fluctuations in carbamazepine concentrations were 79% ± 29% higher than trough levels on a twice-daily dosage schedule and 40% ± 13% higher during four-times-a-day administration. The appearance and intensity of side effects followed the fluctuations in carbamazepine levels and were thus substantially reduced during the four-times-daily regimen. The intrapatient reproducibility of the side effects was good, whereas the thresholds of carbamazepine concentrations at which side effects appeared ranged from 17 to 37 µmole/L.



Author Affiliations

From the Department of Neurology at the Karolinska Institute, Söder Hospital, Stockholm, and the Department of Clinical Pharmacology at the Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden.


Footnotes

Accepted for publication Aug 6, 1983.

Reprint requests to Department of Neurology, Söder Hospital, S-100 64 Stockholm 38, Sweden (Dr Tomson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Extended-Release Formulations in Epilepsy
Verrotti et al.
J Child Neurol 2007;22:419-426.
ABSTRACT  

Therapeutic Drug Monitoring of Mood Stabilizers in Medicaid Patients With Bipolar Disorder
Marcus et al.
Am. J. Psychiatry 1999;156:1014-1018.
ABSTRACT | FULL TEXT  

Cerebellar Atrophy Decreases the Threshold of Carbamazepine Toxicity in Patients With Chronic Focal Epilepsy
Specht et al.
Arch Neurol 1997;54:427-431.
ABSTRACT  

Diurnal Variation of Carbamazepine and Carbamazepine-10,11-epoxide in Plasma and Saliva in Children With Epilepsy: A Comparison Between Conventional and Slow-Release Formulations
Eeg-Olofsson et al.
J Child Neurol 1990;5:159-165.
ABSTRACT  

Rational Therapeutic Drug Monitoring
Friedman and Greenblatt
JAMA 1986;256:2227-2233.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.